Clinical Nurse Specialist · Tulsa, OK
NPI
1104054147
Since 2009
Specialty
Clinical Nurse Specialist
Code 364S00000X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
2000 S Wheeling Ave, Ste 200
Tulsa, OK, 74104
Phone (918) 748-7854
Groups this clinician bills Medicare through
Medicare paid, 2024
$52K
1,965 services
Medicare patients, 2024
301
Average age 72
Drug cost, 2024
$256K
3,778 prescriptions
Company payments, 2025
$372
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Lisha R Porch-Petitt was code J1010 (injection, methylprednisolone acetate, 1 mg), 1,000 times for 17 patients. In total Lisha R Porch-Petitt billed 1,965 services in 12 codes, and Medicare paid $52K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2009-07-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 1,000 | 17 | $0.10 | $102 |
| 99214 Office E&M - Established | Office | 454 | 214 | $67.68 | $31K |
| 99213 Office E&M - Established | Office | 320 | 154 | $46.58 | $15K |
| 99441 Telephone Services | Office | 83 | 66 | $15.17 | $1,259 |
| 99442 Telephone Services | Office | 70 | 53 | $40.79 | $2,856 |
| 20610 Joint Injection | Office | 16 | 14 | $41.23 | $660 |
By year: 2022 $70K for 1,220 services; 2023 $49K for 1,014 services; 2024 $52K for 1,965 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 80307 Drug Tests | 62 | 60 | $59.99 | $3,719 |
| G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 61 | 59 | $112.16 | $6,842 |
Medicare prescription drug claims, 2024
In 2024, the drug Lisha R Porch-Petitt prescribed most often to Medicare patients was Buprenorphine Hcl, with 518 prescriptions and refills. In total Lisha R Porch-Petitt wrote 3,778 Medicare prescriptions that cost $256K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Buprenorphine Hcl Generic | 518 | 522 | 88 | $20K |
| Gabapentin Generic | 411 | 556 | 79 | $6,415 |
| Tramadol Hcl Generic | 407 | 407 | 88 | $3,446 |
| Pregabalin Generic | 299 | 302 | 59 | $4,585 |
| Tizanidine Hcl Generic | 246 | 271 | 54 | $2,553 |
| Baclofen Generic | 244 | 312 | 45 | $3,545 |
| Acetaminophen-Codeine Acetaminophen With Codeine | 183 | 183 | 36 | $4,673 |
| Buprenorphine Generic | 175 | 175 | 35 | $47K |
| Methocarbamol Generic | 144 | 157 | 30 | $1,715 |
| Methylprednisolone Generic | 140 | 140 | 107 | $1,182 |
| Belbuca Buprenorphine Hcl | 124 | 124 | 31 | $109K |
| Cyclobenzaprine Hcl Generic | 109 | 144 | 26 | $1,278 |
| Duloxetine Hcl Generic | 69 | 117 | 15 | $823 |
| Meloxicam Generic | 64 | 104 | 19 | $291 |
| Naltrexone Hcl Generic | 61 | 80 | 11 | $1,759 |
Brand drugs: 210 claims; generic drugs: 3,568 claims; opioid claims: 946.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Lisha R Porch-Petitt $372 ($372 in general payments such as food, travel and fees) from 8 companies. The largest payer was Collegium Pharmaceutical, Inc. with $137.
| Company | Payments | Amount |
|---|---|---|
| Collegium Pharmaceutical, Inc. COLL | 8 | $137 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 4 | $83.96 |
| Medtronic, Inc. MDT | 2 | $43.72 |
| Vertex Pharmaceuticals Incorporated VRTX | 1 | $30.74 |
| Pacira Pharmaceuticals Incorporated PCRX | 1 | $24 |
| Saluda Medical Americas, Inc. | 1 | $20.63 |
| Averitas Pharma Inc. | 1 | $17.98 |
| Zimmer Biomet Holdings, Inc. ZBH | 1 | $13.8 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.